Editas Medicine Outperforms Medical Sector This Year Despite Zacks Rank #2
ByAinvest
Thursday, Jul 31, 2025 11:35 am ET1min read
EDIT--
Editas Medicine (EDIT) and Adherex Technologies Inc. (FENC) have both demonstrated strong performance in the Medical sector during 2023. Editas Medicine, a member of the Medical sector, has gained 98.4% year-to-date (YTD), significantly outperforming the sector's average return of -5.4%. This impressive performance is reflected in the company's Zacks Rank of #2 (Buy) and a Zacks Consensus Estimate for full-year earnings that has moved 0.4% higher within the past quarter [1].
Similarly, Adherex Technologies Inc. (FENC) has also shown robust performance, gaining 33.1% YTD. The stock's Zacks Rank is also #2 (Buy), indicating a strong buy signal. The consensus estimate for Adherex Technologies Inc.'s current year EPS has increased by 360% over the past three months, highlighting the growing optimism among analysts [1].
Both companies belong to the Medical - Biomedical and Genetics industry, which has gained an average of 1.5% YTD. This industry rank is #147 in the Zacks Industry Rank, indicating that Editas Medicine and Adherex Technologies Inc. are performing better than average within their industry group [1].
The strong performance of these stocks can be attributed to their focus on innovation and R&D, as highlighted by their Zacks Rank and the positive changes in their earnings estimates. The alignment of executive compensation with long-term innovation milestones and financial performance is a strategic imperative in the healthcare sector [2]. Companies like Editas Medicine and Adherex Technologies Inc. that prioritize innovation and R&D are better positioned to deliver robust shareholder returns while advancing medical breakthroughs.
Investors interested in the Medical sector should continue to track Editas Medicine and Adherex Technologies Inc. for potential future gains. These stocks have shown a strong ability to outperform their sector and industry peers, making them attractive investment opportunities.
References:
[1] https://www.nasdaq.com/articles/are-medical-stocks-lagging-editas-medicine-edit-year
[2] https://www.ainvest.com/news/aligning-executive-pay-innovation-healthcare-sector-path-long-term-2507/
Editas Medicine (EDIT) has outperformed the Medical sector in 2023, gaining 98.4% year-to-date compared to the sector's average return of -5.4%. The company has a Zacks Rank of #2 (Buy) and a Zacks Consensus Estimate for full-year earnings that has moved 0.4% higher within the past quarter. Adherex Technologies Inc. (FENC) has also outperformed the sector, gaining 33.1% year-to-date and having a Zacks Rank of #2 (Buy).
July 02, 2025Editas Medicine (EDIT) and Adherex Technologies Inc. (FENC) have both demonstrated strong performance in the Medical sector during 2023. Editas Medicine, a member of the Medical sector, has gained 98.4% year-to-date (YTD), significantly outperforming the sector's average return of -5.4%. This impressive performance is reflected in the company's Zacks Rank of #2 (Buy) and a Zacks Consensus Estimate for full-year earnings that has moved 0.4% higher within the past quarter [1].
Similarly, Adherex Technologies Inc. (FENC) has also shown robust performance, gaining 33.1% YTD. The stock's Zacks Rank is also #2 (Buy), indicating a strong buy signal. The consensus estimate for Adherex Technologies Inc.'s current year EPS has increased by 360% over the past three months, highlighting the growing optimism among analysts [1].
Both companies belong to the Medical - Biomedical and Genetics industry, which has gained an average of 1.5% YTD. This industry rank is #147 in the Zacks Industry Rank, indicating that Editas Medicine and Adherex Technologies Inc. are performing better than average within their industry group [1].
The strong performance of these stocks can be attributed to their focus on innovation and R&D, as highlighted by their Zacks Rank and the positive changes in their earnings estimates. The alignment of executive compensation with long-term innovation milestones and financial performance is a strategic imperative in the healthcare sector [2]. Companies like Editas Medicine and Adherex Technologies Inc. that prioritize innovation and R&D are better positioned to deliver robust shareholder returns while advancing medical breakthroughs.
Investors interested in the Medical sector should continue to track Editas Medicine and Adherex Technologies Inc. for potential future gains. These stocks have shown a strong ability to outperform their sector and industry peers, making them attractive investment opportunities.
References:
[1] https://www.nasdaq.com/articles/are-medical-stocks-lagging-editas-medicine-edit-year
[2] https://www.ainvest.com/news/aligning-executive-pay-innovation-healthcare-sector-path-long-term-2507/
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet